This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease.
Strongbridge Biopharma announced the top-line findings from the extended evaluation phase of the pivotal Phase III SONICS study of Recorlev...
Treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue. Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed. The 60 mg strength is only to be used in the treatment of acromegaly.
Signifor (pasireotide)from Novartis, significantly reduced urinary cortisol levels and improved symptoms of Cushing's disease in the largest clinical study of...
Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.
The FDA Endocrinologic and Metabolic Drugs Advisory Committee has voted unanimously in support of the use of Signifor (pasireotide) from...
The FDA has approved Signifor (pasireotide) injection from Novartis, for the treatment of adult patients with Cushing's Disease for whom...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion...